Back to results
US 5,328,909 AGranted
Cyclopropenone derivatives
AssigneeMitsubishi Kasei Corporation
InventorsRyoichi Ando, Yasuhiro Morinaka, Chizuko Takahashi, Yoshikuni Tamao, Akihiro Tobe
Life of this patent
Estimating the term…
Abstract
A novel cyclopropenone derivative (I) which possesses a potent inhibitory activity against thiol protease such as papain, cathepsin B, cathepsin H, cathepsin L, calpain or the like with excellent properties regarding oral absorbance, tissue transference and cell membrane permeability, and are clinically useful in the treatment of various diseases such as muscular dystrophy, amyotrophy. Also provided are a process for producing the compound (I) and a pharmaceutical composition containing the same.
Claims9
A cyclopropenone derivative of general formula (I):
- ##STR1000## wherein R.sup.1 is hydrogen, R.sup.12 --CO--, R.sup.12 --O--CO--, R.sup.12 --NH--CO-- or R.sup.12 --SO.sub.2 --(in which R.sup.12 is C.sub.1 -C.sub.20 alkyl optionally substituted by one or more substituents selected from the consisting of C.sub.3 -C.sub.15 cycloalkyl group, optionally substituted C.sub.6 -C.sub.14 aryl, optionally substituted C.sub.3 -C.sub.15 cycloalkyloxy, optionally substituted C.sub.6 -C.sub.14 aryloxy, optionally substituted C.sub.6 -C.sub.14 arylthio, optionally substituted C.sub.6 -C.sub.14 arylsulfonyl, optionally substituted C.sub.7 -C.sub.20 aralkyloxy, optionally substituted heterocyclic, oxo, hydroxyl, C.sub.1 -C.sub.10 alkoxycarbonyl and carboxyl;
- C.sub.3 -C.sub.15 cycloalkyl;
- optionally substituted C.sub.6 -C.sub.14 aryl or optionally substituted heterocyclic;
- R.sup.2, R.sup.4 and R.sup.6 each is independently hydrogen or C.sub.1 -C.sub.10 alkyl optionally substituted by C.sub.1 -C.sub.5 alkoxy or by C.sub.1 -C.sub.5 alkylthio;
- R.sup.3, R.sup.5 and R.sup.7 each is independently hydrogen, C.sub.1 -C.sub.20 alkyl optionally substituted by C.sub.3 -C.sub.10 cycloalkyl, C.sub.3 -C.sub.10 cycloalkyl or optionally substituted C.sub.7 -C.sub.20 aralkyl;
- R.sup.8 is hydrogen or C.sub.1 -C.sub.20 alkyl;
- R.sup.7 and R.sup.8 taken together may form C.sub.3 -C.sub.15 cycloalkyl;
- R.sup.9 is hydroxy or C.sub.2 -C.sub.20 acyloxy;
- R.sup.10 is hydrogen;
- or R.sup.9 and R.sup.10 taken together may form oxo;
- R.sup.11 is hydrogen, C.sub.1 -C.sub.20 alkyl optionally substituted by C.sub.3 -C.sub.15 cycloalkyl, C.sub.3 -C.sub.15 cycloalkyl, C.sub.2 -C.sub.20 alkenyl, optionally substituted C.sub.6 -C.sub.14 aryl, optionally substituted C.sub.7 -C.sub.20 aralkyl, optionally substituted heterocyclic or --C(R.sup.13)(R.sup.14)--OH (in which R.sup.13 and R.sup.14 each is independently hydrogen, C.sub.1 -C.sub.20 alkyl, optionally substituted C.sub.7 -C.sub.20 aralkyl or optionally substituted C.sub.6 -C.sub.14 aryl, or R.sup.13 and R.sup.14 taken together may form C.sub.3 -C.sub.15 cycloalkyl);
- and n is 0 or 1 or a pharmaceutically acceptable salt thereof.
9 more elements
Dependencies are inferred from the claim text.